The same group also developed E. coli bEVs expressing peptide epitopes of EGFR-EGFRvIII by fusion to the Neiserria meningitidis factor H binding-vIII protein (Nm-fHbp) and described a vaccine-induced antibody response that was associated with inhibition of EGFRvIII-expressing B16F10 tumor growth in mouse models [138]. Here, EGFR is linked to neoplasm.